Contact

Esther Masiá

cribado@cipf.es

TEL: +34 963 289 681
Ext. 2306
FAX: +34 963 289 701

Services


 

The creation and maintenance of a collection of compounds with high chemodiversity are also remarkable objectives of this platform, being able to scale up the experiments for massive screening assays (highthroughput screening; HTS) and select the most active compounds against therapeutic targets of interest. Once the compoundis selected, the service provides the means necessary to develop transport systems (polymer conjugates) aiming to improve the solubility of the active compound, increase its half-life time in the bloodstream,to achieve agreater accumulationin the tumor and inflammatory sites,etc.

 

  • Cell culture (human eukaryotic cell, both in suspension and adherent):
    Primary cultures. Stem cell cultures. Immortalized cell lines (tumor).
  • Assays of molecular biology.

Protein-RNA interaction.

Enzyme activity and competition studies including detection by polarized fluorescence.

HIF (Hypoxia Inducible Factor) activity.

Detection and quantification of protein expression, Western blotting, flow cytometry and immunocytochemistry). As well as RNA and DNA techniques  (RT-PCR, quantitative PCR, semi-quantitativePCR.).

Telomerase Activity.

Antioxidant activity.

Anti-aging activity. (screening and cytomics services)

Nuclear translocation of transcription factors. (eg NFKB) (screening and cytomics services).

  • Viability-toxicity tests: MTT. MTS. ATP.
  • Cell cycle, apoptosis and mitochondrial membrane potential assays, complementary to the cytotoxicity assays. (screening and cytomics services)
  • Full histological processing for work with experimental animals: (from tissues and organs separation and slice until staining the slices).
  • Set up test with high density format.
  • Statistic validation tests.
  • Massive screening of libraries compounds.
  • Secondary evaluation of selected positive results.
  • Search of competitive information. Initial analysis of the novelty for intellectual protection.
  • Development of Medicinal Chemistry "Hit to Lead".
  • Development of transport systems (polymer conjugates) for the selected compounds.
  • Validation of biological activity in animal models.
  • Characterization of external compounds.